Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
But4.5
Butyrate – Forschung
Hilft wahrscheinlich
71 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Butyrate scheint in 10 von 10 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2008–2026 mit einer typischen Studiengröße von 66 Teilnehmenden.
Basierend auf 71 Studien · 14 Meta-Analysen · 20 RCTs · 34,928 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
10geholfen· 61 weitere ohne bewertete Effektdaten
Nach Outcome
Digestive healthKleine RCTs zu Reizdarmsyndrom/Colitis deuten auf verringerte gastrointestinale Beschwerden hin; überwiegend indirekte Daten · 2-4 Wochen
Hilft wahrscheinlich67 Studien
Therapeutic & clinical
Hilft wahrscheinlich13 Studien
Glucose & metabolicMechanistische SCFA-Rolle; keine direkten Ergebnisse zur Supplementierung · 4-8 Wochen
Überwiegend Mechanismus / Beobachtung7 Studien
InflammationKleine Studien deuten auf geringere Darmentzündung hin; starker Mechanismus, begrenzte direkte Evidenz · 4-8 Wochen
Überwiegend Mechanismus / Beobachtung5 Studien
Heart & blood pressure
Überwiegend Mechanismus / Beobachtung4 Studien
Depression & mood
Überwiegend Mechanismus / Beobachtung4 Studien
Weight management
Überwiegend Mechanismus / Beobachtung3 Studien
Cholesterol & lipids
Überwiegend Mechanismus / Beobachtung3 Studien
Cognitive function
Zu wenige bewertete Studien2 Studien
Anxiety & stress
Zu wenige bewertete Studien2 Studien
Immune supportPlausible Modulation von Darmbarriere/Immunsystem; wenig direkte Evidenz zur Supplementierung · 4-8 Wochen
Zu wenige bewertete Studien2 Studien
Bone health
Zu wenige bewertete Studien1 Studie
Skin health
Zu wenige bewertete Studien1 Studie
Safety profile
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 44 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
57%
über Studien hinweg
Untersuchte Personen
35k
typische Studie: 66 Personen
Stärkste Designs
34
14 gepoolt, 20 randomisiert
Zeigte Nutzen
100%
10/10 Studien
Wie lange Studien liefen
1–4 Wochen
1
Untersuchte Populationen
Adults2
Chronic kidney disease patients1
Patients with depressive disorder1
Patients with depression, bipolar disorder, schizophrenia, and anxiety1
Aktives Forschungsgebiet
62 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
200820172026
1Circulating acetate and propionate levelsMeta-Analysen=9,661 · very large study2026
CKD is associated with a profound systemic reduction in acetate and propionate, supporting the model of a compromised gut-kidney axis based on converging evidence.
Thakur D et al. · Nutrients (2026)
Borderline
Quantitative synthesis revealed a significant and consistent systemic depletion of circulating acetate and propionate in adult CKD patients compared to healthy controls (p < 0.05).
CKD is associated with a profound systemic reduction in acetate and propionate, supporting the model of a compromised gut-kidney axis based on converging evidence.
The divergent results for butyrate in paediatric versus adult populations suggest that SCFA metabolism is influenced by age-related factors or compensatory mechanisms.
2Chao1 diversity indexMeta-AnalyseCited 86×n=2,091 · very large study2023
Depressive disorder is characterized by an increase of pro-inflammatory bacteria, while anti-inflammatory butyrate-producing genera are depleted.
Gao M et al. · Translational psychiatry (2023)
Spürbar Nutzen
← SchlechterKein EffektBesser →
A random-effects model with restricted maximum-likelihood estimator was used to synthesize the effect size (assessed by standardized mean difference [SMD]) across studies.
In subgroup analyses with regional variations(east/west) as a predictor, patients who were in the West had a lower Chao1 level (SMD -0.42[-0.74 to -0.10]).
Subgroup meta-analysis showed Firmicutes level was decreased in patients with depressive disorder who were medication-free (SMD -1.54[-2.36 to -0.72]), but Bacteroidetes level was increased (SMD -0.90[0.07 to 1.72]).
3Phylogenetic diversity in psychiatric disordersMeta-AnalyseCited 534×n=1,519 · large study2021
This systematic review and meta-analysis found that gut microbiota perturbations were associated with a transdiagnostic pattern with a depletion of certain anti-inflammatory butyrate-producing bacteria and an enrichment of pro-inflammatory bacteria in patients with depression, bipolar disorder, schizophrenia, and anxiety.
Nikolova VL et al. · JAMA psychiatry (2021)
Spürbar Nutzen
← SchlechterKein EffektBesser →
There was a small decrease in phylogenetic diversity (SMD = -0.24; 95% CI, -0.47 to -0.001) and no significant differences in Shannon and Simpson indices.
5Gut microbiota composition in psychiatric disordersSystematische ÜbersichtCited 374×n=2,510 · very large study2022
Our syntheses also identified specific bacterial taxa commonly associated with mental disorders, including lower levels of bacterial genera that produce short-chain fatty acids (e.g. butyrate), higher levels of lactic acid-producing bacteria, and higher levels of bacteria associated with glutamate and GABA metabolism.
McGuinness AJ et al. · Molecular psychiatry (2022)
We also observed substantial heterogeneity across studies with regards to methodologies and reporting.
Further prospective and experimental research using new tools and robust guidelines hold promise for improving our understanding of the role of the gut microbiota in mental and brain health and the development of interventions based on modification of gut microbiota.
6Meta-AnalyseCited 482×n=2,099 · very large study2018
Dietary fiber intervention, particularly involving fructans and galacto-oligosaccharides, leads to higher fecal abundance of Bifidobacterium and Lactobacillus spp. but does not affect α-diversity.
So D et al. · The American journal of clinical nutrition (2018)
Dietary fiber intervention, particularly involving fructans and galacto-oligosaccharides, leads to higher fecal abundance of Bifidobacterium and Lactobacillus spp. but does not affect α-diversity.
Further research is required to better understand the role of individual fiber types on the growth of microbes and the overall gut microbial community.
This review was registered at PROSPERO as CRD42016053101.
7Biologics response prediction in IBDSystematische ÜbersichtCited 36×n=38 · small study2024
IBD patients who responded well to vedolizumab treatment had higher levels of specific bacteria that produce butyrate, along with increased levels of metabolites such as butyrate, branched-chain am...
Wang C et al. · Microbiological research (2024)
IBD patients who responded well to vedolizumab treatment had higher levels of specific bacteria that produce butyrate, along with increased levels of metabolites such as butyrate, branched-chain amino acids and acetamide following vedolizumab treatment.
Crohn's disease patients who responded positively to ustekinumab treatment showed higher levels of Faecalibacterium and lower levels of Escherichia/Shigella.
Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Sasaki M et al. · Allergy (2024)
Overall, there was some evidence showing that the three main SCFAs (acetate, propionate and butyrate) in the first few years of life had a protective effect against allergic diseases, especially for atopic dermatitis, wheeze or asthma and IgE-mediated food allergy in childhood.
The association between each SCFA and allergic disease appeared to be different by disease and the age of assessment.
Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Our research found universally applicable biomarkers and investigated their potential roles in promoting human health at high altitudes.
Zhao H et al. · Gut microbes (2024)
Functional analysis and qPCR revealed that butyrate may be a functional metabolite in high-altitude adaptation.
A high-altitude rat model showed that butyrate reduced intestinal damage caused by high altitudes.
According to cell experiments, butyrate may downregulate hypoxia-inducible factor-1α (HIF-1α) expression and blunt cellular responses to hypoxic stress.
In this study, we demonstrated that the promising substate (prebiotics), microbe (probiotics), metabolite (postbiotics), and target are suitable for obsesity treatment, providing a microbiome basis for further research.
Oh KK et al. · Cells (2022)
Then, we implemented protein-protein interaction (PPI) networks with 342 overlapping target, another subnetwork was constructed with the top 30% degree centrality (DC), and the final core networks were obtained after screening the top 30% betweenness centrality (BC).
The final core targets were IL6, AKT1, and ALB.
We showed that the three core targets interacted with three other components via the MSMT network in alleviating obesity, i.e., four microbiota, two substrates, and six metabolites.
Although a definitive interpretation is limited by the cross-sectional design of published reports, we integrated findings of microbial composition and downstream functional pathways and metabolites, offering possible explanations regarding age-related processes.
Badal VD et al. · Nutrients (2020)
Beta diversity distances significantly differed across various developmental stages and were different even between oldest-old and younger-old adults.
Differences in taxonomic composition and functional potential varied across studies, but Akkermansia was most consistently reported to be relatively more abundant with aging, whereas Faecalibacterium, Bacteroidaceae, and Lachnospiraceae were relatively reduced.
Although a definitive interpretation is limited by the cross-sectional design of published reports, we integrated findings of microbial composition and downstream functional pathways and metabolites, offering possible explanations regarding age-related processes.
12gut microbiota and short-chain fatty acids in cardiometabolic HFpEFSystematische Übersicht2026
Targeting gut-heart axis and SCFAs pathways may represent a biologically plausible and low-risk approach that could help attenuate inflammation and metabolic dysfunctions in patients with cardiometabolic HFpEF, offering novel potential therapeutic targets for their management.
This review summarizes current evidence linking gut microbiota dysfunction to cardiometabolic HFpEF, elucidates the mechanistic role of SCFAs, and discusses nutritional approaches aimed at enhancing their production and activity.
Targeting gut-heart axis and SCFAs pathways may represent a biologically plausible and low-risk approach that could help attenuate inflammation and metabolic dysfunctions in patients with cardiometabolic HFpEF, offering novel potential therapeutic targets for their management.
13Efficacy of sodium butyrate formulations in intestinal diseasesSystematische Übersicht2026
Differences between clinical study results suggests that formulation of butyrate impacts its efficacy.
Caban M et al. · Digestive diseases and sciences (2026)
Therefore, we suggest that clinical results should be assessed in relation to specific preparations.
Our summary confirms that specific microencapsulated versions, including those utilizing the MSB® technology are valuable therapeutic options supporting the treatment of intestinal diseases.
Differences between clinical study results suggests that formulation of butyrate impacts its efficacy.
14Gut-brain health and systemic inflammationSystematische Übersicht2026
Therapeutic strategies that restore BPB populations and butyrate levels, such as prebiotics, dietary fiber, and microbiota-targeted interventions, hold promise for mitigating inflammation and enhancing systemic health through microbiome modulation.
Snodgrass JL et al. · International journal of molecular sciences (2026)
Butyrate supports colonocyte energy metabolism, reinforces epithelial barrier function, regulates goblet cell mucus production, and exerts anti-inflammatory effects via histone deacetylase inhibition and G-protein-coupled receptor signaling.
The depletion of BPB and the resultant butyrate deficiency may represent a unifying pathophysiological mechanism underlying these conditions.
Therapeutic strategies that restore BPB populations and butyrate levels, such as prebiotics, dietary fiber, and microbiota-targeted interventions, hold promise for mitigating inflammation and enhancing systemic health through microbiome modulation.
Integrating these personalised, evidence-informed protocols may support the optimisation of physiological resilience and performance.
Biliński K et al. · Nutrients (2026)
These SCFAs serve as energy substrates that may enhance glucose uptake, lipid oxidation, and glycogen storage in skeletal muscle.
Evidence suggests that travel-related stressors-including dehydration, psychological stress, and shifts toward highly processed diets-further exacerbate the loss of beneficial taxa.
To mitigate these effects, this article proposes evidence-informed strategies: timed light exposure to reset the master clock, chronobiotic meal timing to entrain peripheral tissues, and targeted symbiotic supplementation to restore SCFA-producing populations.
16gestational weight gain reductionMeta-Analysen=46 · small study2025
Future studies should focus on personalized probiotic interventions and long-term maternal-child health effects.
Jia X, Sun S, Ci Z. · Frontiers in cellular and infection microbiology (2025)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
Results Probiotic supplementation, especially multispecies formulations, initiated in the first trimester led to a mean reduction in gestational weight gain (GWG) of 1.25 kg (95% CI: -1.78 to -0.72 kg; p < 0.001) compared to controls.
Furthermore, postpartum weight retention was reduced by an average of 1.05 kg (95% CI: -1.53 to -0.58 kg; p < 0.001) when probiotic use extended into the postpartum period.
The heterogeneity in strains, dosage, and duration and pooled analysis consistently favored probiotic intervention.
17Butyrate effectiveness in Parkinson's diseaseSystematische Übersicht2025
Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences.
Abreu AE et al. · Neuroscience bulletin (2025)
This review examines butyrate's origins, functions, and mechanisms in the gut, its impact on the gut-brain axis, and its relevance in both "brain-first" and "gut-first" PD models.
We also explore the effects of butyrate supplementation in animal models and human clinical studies, highlighting its promise as a therapeutic agent for PD.
The understanding of butyrate as a versatile metabolite may pave the way for innovative strategies to prevent or manage PD, stressing the need for integrated approaches targeting both the nervous and gastrointestinal systems.
Future Perspectives : Expand data on underrepresented groups (African Americans, Latinos), unify SCFA detection methods, and conduct long-term RCTs to validate intervention efficacy and "genetics-microbiota-metabolism" crosstalk-critical for CRC precision prevention.
He Y, Peng K, Tan J, Hao Y, Zhang S, Gao C, Li L. · Nutrients (2025)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Results : Total SCFAs were negatively associated with CRC (OR = 0.78, 95% CrI: 0.65-0.92) and A-CRA (OR = 0.72, 95% CrI: 0.59-0.87), with butyrate showing the strongest protective effect (CRC: OR = 0.63, 95% CrI: 0.51-0.77).
Ethnic heterogeneity was significant: Europeans had the strongest protection (OR = 0.71), Asians had weaker protection (OR = 0.86), and African Americans had the lowest fecal SCFA levels and the highest CRC risk.
Fecal SCFAs showed a stronger CRC association than serum/plasma SCFAs (OR = 0.73 vs. 0.85).
Maddirevula MK, Nelson VK, Soliman M, Alanazi BK, Hegazy AMS, Baig HA, Soliman AM, Alanazi M. · Frontiers in cellular and infection microbiology (2025)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Interventions significantly reduced total testosterone (MD -0.19 ng/mL, 95% CI -0.30 to -0.08), LH/FSH ratio (SMD -0.46; 95% CI -0.66 to -0.26), fasting insulin (MD -2.4 µIU/mL; 95% CI -3.9 to -0.9), and HOMA-IR (MD -0.49; 95% CI -0.78 to -0.19).
HDL-C increased modestly (MD + 3.2 mg/dL; 95% CI + 0.7 to +5.6).
Evidence certainty was moderate for insulin-related outcomes and low for sex-hormone outcomes.
20Immunity, infections, inflammation and vaccine responsesSystematische Übersicht2025
Further research is needed to clarify the mechanisms involved and to optimize health applications.
Arioz Tunc H et al. · Critical reviews in food science and nutrition (2025)
A systematic review of human studies showed that prebiotics, including GOS, FOS, and 2'-fucosyllactose (2FL), reduced infections and increased IgA in healthy infants, while yeast β-glucan reduced respiratory infection symptoms in healthy adults.
Yeast β-glucan and GOS supplementation resulted in improvements in NK cell activity.
Some effects on vaccine efficacy were noted in young adults, but the overall impact of NDCs and prebiotics on vaccination and systemic inflammation was inconsistent.